Page 115 - 《中国药房》2024年9期
P. 115

2种喜树碱类拓扑异构酶1抑制剂ADE信号的挖掘与分析                                                              Δ



                                                             2
                                                     1
                                                                      2
                                    1
                           2 #
          吴镇江 ,刘建军 ,白翔宇 ,杨茂凡 ,樊文海 ,王 攀 ,杨钧淞(1. 川北医学院临床医学院,四川 南充
                 1*
                                            3
          637000;2.川北医学院附属医院胃肠外科,四川 南充 637000;3.川北医学院附属医院重症医学科,四川 南充
          637000)
          中图分类号  R969.3;R979.1      文献标志码  A      文章编号  1001-0408(2024)09-1133-06
          DOI  10.6039/j.issn.1001-0408.2024.09.19

          摘  要  目的  对2种喜树碱类拓扑异构酶1抑制剂伊立替康和托泊替康的药物不良事件(ADE)信号进行挖掘与分析,为临床安
          全用药提供参考。方法  基于美国FDA不良事件报告系统(FAERS)数据库,提取2004年1月1日至2023年3月31日上述2种药物
          的ADE报告数据。对数据进行处理后,采用报告比值比法联合贝叶斯置信传播神经网络法进行信号挖掘,并进行分析。结果  共
          筛选出相关ADE报告14 738份,其中伊立替康11 483份,托泊替康3 255份。伊立替康的ADE报告性别以男性为主,托泊替康以
          女性为主;两药的使用患者年龄均主要集中于45~<75岁。共检测出847个信号,累及24个系统器官分类(SOC)。其中,伊立替
          康检测出565个信号,累及24个SOC,主要集中于胃肠系统疾病、全身性疾病及给药部位各种反应、血液及淋巴系统疾病等;报告
          频数最多的ADE为腹泻,信号强度最大的ADE为胆碱能综合征。托泊替康检测出282个信号,累及22个SOC,主要集中于全身
          性疾病及给药部位各种反应、各类检查、血液及淋巴系统疾病、胃肠系统疾病等;报告频数较多的ADE为死亡和贫血,信号强度最
          大的ADE为发热性骨髓再生障碍。伊立替康的转移性结肠直肠癌、外周感觉神经病、脂肪性肝炎等ADE和托泊替康的虹膜萎缩、
          视网膜变性、玻璃体积血等ADE均未在各自说明书中提及。结论  伊立替康和托泊替康的ADE主要累及消化系统和血液系统,临
          床上应重点监测;伊立替康所引起的胆碱能综合征应引起关注。除此之外,使用伊立替康的患者还应关注转移性结肠直肠癌、外
          周感觉神经病、脂肪性肝炎、蛋白尿等ADE,使用托泊替康的患者应加强眼器官疾病的监测,以确保用药安全。
          关键词  喜树碱类拓扑异构酶1抑制剂;伊立替康;托泊替康;胆碱能综合征;虹膜萎缩;视网膜变性;玻璃体积血

          Mining and analysis of ADE signals of two camptothecin topoisomerase 1 inhibitors
          WU Zhenjiang ,LIU Jianjun ,BAI Xiangyu ,YANG Maofan ,FAN Wenhai ,WANG Pan ,YANG Junsong
                                                                  3
                                                  1
                                    2
                                                                               1
                                                                                                            2
                       1
                                                                                            2
         (1. School of Clinical Medicine, North Sichuan Medical College, Sichuan Nanchong 637000, China;2. Dept. of
          Gastrointestinal Surgery, the Affiliated Hospital of North Sichuan Medical College, Sichuan Nanchong 637000,
          China;3.  Dept.  of  Intensive  Care  Unit,  the  Affiliated  Hospital  of  North  Sichuan  Medical  College,  Sichuan
          Nanchong 637000, China)
          ABSTRACT   OBJECTIVE  To  mine  and  analyze  the  adverse  drug  events (ADE)  signals  of  two  camptothecin  topoisomerase  1
          inhibitors,  i.e.  irinotecan  and  topotecan,  and  to  provide  reference  for  clinical  medication  safety.  METHODS  Based  on  the  U.S.
          Food  and  Drug Administration Adverse  Event  Reporting  System (FAERS)  database, ADE  report  data  for  the  aforementioned  two
          drugs  were  extracted  from  January  1,  2004  to  March  31,  2023. After  processing  the  data,  signal  mining  was  conducted  by  using
          the reporting odds ratio in conjunction with the Bayesian confidence propagation neural network, followed by analysis. RESULTS
          A  total  of  14  738  relevant  ADE  reports  were  screened,  among  which  11  483  were  associated  with  irinotecan  and  3  255  with
          topotecan. The ADE  reports  for  irinotecan  were  predominantly  male,  whereas  for  topotecan,  they  were  predominantly  female;  the
          age  of  patients  using  the  two  drugs  mainly  concentrated  in  45-<75  years  old. A  total  of  847  signals  were  detected,  involving  24
          system  organ  classes (SOCs). Among  them,  565  signals  of  irinotecan  were  detected,  involving  24  SOCs,  primarily  concentrating
          on  gastrointestinal  disorders,  general  disorders  and  administration  site  conditions,  blood  and  lymphatic  system  disorders;  the  most
          frequently  reported ADE  was  diarrhea,  and  the ADE  with  the  strongest  signal  intensity  was  cholinergic  syndrome. A  total  of  282
          signals  of  topotecan  were  detected,  involving  22  SOCs,  primarily  concentrating  on  general  disorders  and  administration  site
                                                             conditions,  investigations,  blood  and  lymphatic  system
             Δ 基金项目 川北医学院科研发展计划项目(No.7500520021)             disorders,  and  gastrointestinal  disorders;  the  most  frequently
             * 第一作者 硕 士 研 究 生 。 研 究 方 向 :胃 肠 肿 瘤 。 E-mail:
                                                             reported ADEs  were  death  and  anemia,  and  the ADE  with  the
          18282863467@139.com
             # 通信作者 主治医师,硕士生导师,博士。研究方向:胃肠肿瘤。                 strongest  signal  intensity  was  febrile  bone  marrow  aplasia.
          E-mail:1511323937@qq.com                           ADE  signals  for  irinotecan  such  as  metastatic  colorectal


          中国药房  2024年第35卷第9期                                                China Pharmacy  2024 Vol. 35  No. 9    · 1133 ·
   110   111   112   113   114   115   116   117   118   119   120